Institution statistics

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON - Spain 

Ranking results:

Past rankings:
2019
Criterium:Position:
Overall Score:800-900
Total Project Funding per Partner:> 1000
Total Number of Projects:800-900
2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:900-1000
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2015
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:500-600
Total Number of Projects:700-800
Networking Rank (Reputation):> 1000
Partner Constancy:800-900
Project Leadership Index:200-300
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:69
Total Project Funding:> 1000
Networking Rank (Reputation):900-1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
Ranking timeline:

European project participation (2010-01-01 - 2021-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 27
As coordinator: 1
As participant: 20
Sole participant: 6
Coordinator / Participant Ratio: 0.05*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 12.958.834 83.312 2
2019 172.932 24.576.884 1.499.930 1 3
2018 148.875 17.102.522 1.629.594 1 3
2017 0 20.200.000 150.000 1
2016 147.750 7.113.779 495.729 1 1
2015 6.146.992 7.359.629 1.731.328 2 2
2014 0 1.730.700 1.730.700 1
2013 0 8.998.350 590.032 2
2012 233.705 150.000 383.705 1 1
2011 0 25.660.240 2.661.578 4
2010 100.000 0 100.000 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
UNIVERSITA DEGLI STUDI DI TORINO7
STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS6
INSTITUT CURIE5
CHARITE UNIVERSITAETSMEDIZIN BERLIN4
EUROPEAN MOLECULAR BIOLOGY LABORATORY4
INSTITUT CATALA D'ONCOLOGIA4
ACADEMISCH ZIEKENHUIS GRONINGEN3
AGENDIA NV3
DEUTSCHES KREBSFORSCHUNGSZENTRUM3
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM3
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL3
KATHOLIEKE UNIVERSITEIT LEUVEN3
LUDWIG MAXIMILIANS UNIVERSITAET MUENCHEN3
MASARYKOVA UNIVERZITA3
ROYAL COLLEGE OF SURGEONS IN IRELAND3
STICHTING VUMC3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD3
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE3
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
EUROPEAN CANCER ORGANISATION2
EUROPEAN CANCER PATIENT COALITION2
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON INSTITUT DE RECERCA2
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE2
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III2
FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON2
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA FUNDACION INCLIVA2
HOSPITAL UNIVERSITARIO DE FUENLABRADA2
INSTITUT GUSTAVE ROUSSY2
INSTITUT JULES BORDET2
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE2
ISTITUTO EUROPEO DI ONCOLOGIA2
JANSSEN PHARMACEUTICA NV2
NOVARTIS PHARMA2
OSLO UNIVERSITETSSYKEHUS HF2
PINTAIL2
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL2
TAKEDA DEVELOPMENT CENTRE EUROPE2
UNIVERSITAETSKLINIKUM HEIDELBERG2
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN2
UNIVERSITY OF HELSINKI2
UNIVERSITY OF NEWCASTLE UPON TYNE2
VIB VZW2
VRIJE UNIVERSITEIT BRUSSEL2
ABBVIE INC1
ACADEMISCH ZIEKENHUIS LEIDEN1
AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA1
AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS1
ALEXANDER FLEMING1
ALLEANZA CONTRO IL CANCRO1
AMGEN1
ANAXOMICS BIOTECH S L1
ANTAROS MEDICAL AB1
ARIANA PHARMACEUTICALS1
ARTTIC IN BRUSSELS SPRL1
BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACION1
BARTS AND THE LONDON NHS TRUST1
BAYER1
BAYER PHARMA1
BELFAST HEALTH AND SOCIAL CARE TRUST1
BELGIAN NUCLEAR RESEARCH CENTRE1
BENGURION UNIVERSITY OF THE NEGEV1
BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM1
BIOKERALTY RESEARCH INSTITUTE AIE1
BMD SOFTWARE LDA1
BUNDESAMT FUER STRAHLENSCHUTZ1
BUNDESINSTITUT FUR ARZNEIMITTEL UND MEDIZINPRODUKTE1
CABALLERO LLANO CARMELO CESAR1
CELGENE MANAGEMENT SARL1
CENTRE D'ETUDE ET DE RECHERCHES VETERINAIRES ET AGROCHIMIQUES1
CENTRE DE REGULACIO GENOMICA1
CENTRE EUROPEEN DE RECHERCHE EN BIOLOGIE ET MEDECINE1
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE1
CHEMICELL1
CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY1
COMITE EUROPEEN DE COORDINATION DES INDUSTRIES RADIOLOGIQUES ELECTROMEDICALES ET D INFORMATIQUE DE SANTE AISBL1
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER1
CONSORCIO MAR PARC DE SALUT DE BARCELONA1
DANISH CANCER SOCIETY1
DE CLERCQ & PARTNERS1
EBERHARD KARLS UNIVERSITAET TUEBINGEN1
ECANCERMEDICALSCIENCE1
EIBIR GEMEINNUTZIGE GMBH ZUR FORDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG1
EPIGENOMICS1
EUROPEAN ALLIANCE FOR MEDICAL RADIATION PROTECTION RESEARCH EUROPAISCHE ALLIANZ FUR STRAHLENSCHUTZFORSCHUNG IM MEDIZIN1
EUROPEAN ALLIANCE FOR PERSONALISED MEDICINE ASBL1
EUROPEAN CANCER PATIENT COALITION1
EUROPEAN GROUP FOR BLOOD AND MARROW TRANSPLANTATION1
EUROPEAN HEMATOLOGY ASSOCIATION1
EUROPEAN ORGANIZATION FOR NUCLEAR RESEARCH1
EUROPEAN RESEARCH INITIATIVE ON CLL EV1
EUROPEAN UNIVERSITY CYPRUS1
F HOFFMANNLA ROCHE1
FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS1
FONDAZIONE TOSCANA GABRIELE MONASTERIO PER LA RICERCA MEDICA E DI SANITA PUBBLICA1
FORSCHUNGSVERBUND BERLIN EV1
FOUNDATION MEDICINE INC1
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS1
Constancy:

Total number of partners:293

Partner loyalty:
Frequent Partner: (> 2 projects): 69
Rare Partner: 224

Frequent / Rare Partner Ratio: 0.31

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES5
RTD HORIZONTAL TOPICS5

Project overview:

Start dateProjectacronymrolefundingpartners
2020-09-01EURopeAn MEDical application and Radiation prOteCtion Concept: strategic research agenda aNd ROadmap interLinking to heaLth and digitisation aspects EURAMED rocc-n-rollparticipant1.959.17529
2020-01-01NGS diagnostics in 21st century oncology: the best, for all, at all times oncNGSparticipant10.999.65914
2019-10-01Immune-Image: Specific Imaging of Immune Cell Dynamics Using Novel Tracer Strategies Immune-Imageparticipant15.000.00022
2019-05-01Co-targeting androgen receptor signalling and DNA damage repair for precision therapy in advanced prostate cancer AR-DDRcoordinator172.9321
2019-01-01CeLac and European consortium for a personalized medicine approach to Gastric Cancer LEGACyparticipant3.577.43111
2019-01-01EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine. EUCANCanparticipant5.999.45318
2018-07-01Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types. SYST-iMYCcoordinator148.8751
2018-02-01EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts EDIReXparticipant5.156.19919
2018-01-01Systems Medicine of Metabolic-Signaling Networks: A New Concept for Breast Cancer Patient Stratification MESI-STRATparticipant5.949.96415
2018-01-01Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions COLOSSUSparticipant5.996.36014
2017-01-01Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY - Sofia ref.: 116026 HARMONYparticipant20.200.00053
2016-08-01Developing an anti-Myc cell-penetrating peptide for cancer treatment GBM-CPPcoordinator147.7501
2016-04-01Nanomedicine upscaling for early clinical phases of multimodal cancer therapy NoCanTherparticipant7.113.77912
2015-11-01Deciphering PI3K biology in health and disease Phdparticipant3.896.14813
2015-10-01Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) MoTriColorcoordinator5.996.99211
2015-07-01Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. CSC-IScoordinator150.0001
2015-05-01Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities (MedBioinformatics) MedBioinformaticsparticipant3.463.4819
2014-05-01Pushing Myc inhibition towards the clinic MYCINHIBINCLINICparticipant1.730.7001
2013-12-01A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor PF-02341066 in KRASMT and KRASWT (with aberrant c-MET) Colorectal Cancer Patients MERCURICparticipant5.999.99513
2013-03-01WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHERparticipant2.998.35511
2012-12-01Targeting Cancer Stem Cells (CSC) for the development of more effective treatments to cure cancer patients ANTI-CSCparticipant150.0001
2012-06-01Role of Notch signaling pathway in Glioma Stem Cells Notch pathway in GSCcoordinator233.7051
2011-01-01Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes RATHERparticipant5.995.7868
2011-01-01OVErcoming Resistance to anti-HER2 therapy OVER-HER2participant1.666.7001
2011-01-01Modelling and predicting sensitivity to targeted therapies in colorectal cancers COLTHERESparticipant5.999.30011
2011-01-01A European Platform for Translational Cancer Research EUROCANPLATFORMparticipant11.998.45428
2010-05-01Pathway-based Secretomes in Breast Cancer Biomarker Discovery PathSec-BCa-BMcoordinator100.0001
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum